Recombinant_granulocyte-macrophage_colony-stimulating_factor_after_autologous_bone_marrow_transplantation_for_lymphoid_cancer._BACKGROUND._The_period_of_neutropenia_after_autologous_bone_marrow_transplantation_results_in_substantial_morbidity_and_mortality._The_results_of_previous_phase_I-II_clinical_trials_suggest_that_recombinant_human_granulocyte-macrophage_colony-stimulating_factor_(rhGM-CSF)_may_accelerate_neutrophil_recovery_and_thereby_reduce_complications_in_patients_after_autologous_bone_marrow_transplantation._METHODS._We_conducted_a_randomized,_double-blind,_placebo-controlled_trial_at_three_institutions._The_study_design_and_treatment_schedules_were_identical,_and_the_results_were_pooled_for_analysis._One_hundred_twenty-eight_patients_were_enrolled._Sixty-five_patients_received_rhGM-CSF_in_a_two-hour_intravenous_infusion_daily_for_21_days,_starting_within_four_hours_of_the_marrow_infusion,_and_63_patients_received_placebo._RESULTS._No_toxic_effects_specifically_ascribed_to_rhGM-CSF_were_observed._The_patients_given_rhGM-CSF_had_a_recovery_of_the_neutrophil_count_to_500_x_10(6)_per_liter_7_days_earlier_than_the_patients_who_received_placebo_(19_vs._26_days,_P_less_than_0.001),_had_fewer_infections,_required_3_fewer_days_of_antibiotic_administration_(24_vs._27_days,_P_=_0.009),_and_required_6_fewer_days_of_initial_hospitalization_(median,_27_vs._33_days;_P_=_0.01)._There_was_no_difference_in_the_survival_rate_at_day_100._CONCLUSIONS._In_patients_undergoing_autologous_bone_marrow_transplantation_for_lymphoid_neoplasia,_rhGM-CSF_significantly_lessens_morbidity._Further_studies_will_be_required_to_establish_its_optimal_dosage_and_schedule_of_administration.